JohnMoehrke Consent with Segmented data
0.1.0-current - ci-build
JohnMoehrke Consent with Segmented data
0.1.0-current - ci-build
JohnMoehrke Consent with Segmented data, published by John Moehrke (himself). This guide is not an authorized publication; it is the continuous build for version 0.1.0-current built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/JohnMoehrke/ConsentWithSegmentation/ and changes regularly. See the Directory of published versions
| Official URL: http://johnmoehrke.github.io/ConsentWithSegmentation/ValueSet/SlsSensitiveHIV | Version: 0.1.0-current | |||
| Standards status: Draft | Maturity Level: 0 | Computable Name: SlsSensitiveHIV | ||
HIV/AIDS information
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
Generated Narrative: ValueSet SlsSensitiveHIV
This value set includes codes based on the following rules:
Generated Narrative: ValueSet
Expansion based on:
This value set contains 162 concepts
| Code | System | Display |
| 0575F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna control plan of care, documented (hiv) |
| 3292F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv testing ordered or documented and reviewed during the first or second prenatal visit (pre-cr) |
| 3490F | http://www.nlm.nih.gov/research/umls/hcpcs | History of aids-defining condition (hiv) |
| 3491F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv indeterminate (infants of undetermined hiv status born of hiv-infected mothers) (hiv) |
| 3492F | http://www.nlm.nih.gov/research/umls/hcpcs | History of nadir cd4+ cell count <350 cells/mm (hiv) |
| 3493F | http://www.nlm.nih.gov/research/umls/hcpcs | No history of nadir cd4+ cell count <350 cells/mmand no history of aids-defining condition (hiv) |
| 3494F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count <200 cells/mm3 (hiv) |
| 3495F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count 200 - 499 cells/mm3 (hiv) |
| 3496F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count >=500 cells/mm3 (hiv) |
| 3497F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell percentage <15% (hiv) |
| 3498F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell percentage >/=15% (hiv) |
| 3500F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count or cd4+ cell percentage documented as performed (hiv) |
| 3502F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna viral load below limits of quantification (hiv) |
| 3503F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna viral load not below limits of quantification (hiv) |
| 3510F | http://www.nlm.nih.gov/research/umls/hcpcs | Documentation that tuberculosis (tb) screening test performed and results interpreted (hiv) (ibd) |
| 3511F | http://www.nlm.nih.gov/research/umls/hcpcs | Chlamydia and gonorrhea screenings documented as performed (hiv) |
| 3512F | http://www.nlm.nih.gov/research/umls/hcpcs | Syphilis screening documented as performed (hiv) |
| 3513F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis b screening documented as performed (hiv) |
| 3514F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis c screening documented as performed (hiv) |
| 3515F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient has documented immunity to hepatitis c (hiv) |
| 4149F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis b vaccine injection administered or previously received (hep-c, hiv) (ibd) |
| 4270F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient receiving potent antiretroviral therapy for 6 months or longer (hiv) |
| 4271F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (hiv) |
| 4274F | http://www.nlm.nih.gov/research/umls/hcpcs | Influenza immunization administered or previously received (hiv) (p-esrd) |
| 4276F | http://www.nlm.nih.gov/research/umls/hcpcs | Potent antiretroviral therapy prescribed (hiv) |
| 4279F | http://www.nlm.nih.gov/research/umls/hcpcs | Pneumocystis jiroveci pneumonia prophylaxis prescribed (hiv) |
| 4280F | http://www.nlm.nih.gov/research/umls/hcpcs | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count or percentage (hiv) |
| 4290F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient screened for injection drug use (hiv) |
| 4293F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient screened for high-risk sexual behavior (hiv) |
| 86689 | http://www.nlm.nih.gov/research/umls/hcpcs | Confirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV |
| 86701 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV -1 virus |
| 86702 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV-2 virus |
| 86703 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV-1 and HIV-2 virus |
| 87389 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2 antibodies |
| 87390 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-1 antigen |
| 87391 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-2 antigen |
| 87534 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, direct probe technique |
| 87535 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, amplified probe technique |
| 87536 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, quantification |
| 87537 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, direct probe technique |
| 87538 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, amplified probe technique |
| 87539 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, quantification |
| 87900 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent drug susceptibility analysis |
| 87901 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus |
| 87903 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested |
| 87904 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, each additional drug tested |
| 87906 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, other region |
| G0432 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening |
| G0433 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening |
| G0435 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening |
| S3645 | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv-1 antibody testing of oral mucosal transudate |
| 136.3 | http://hl7.org/fhir/sid/icd-9-cm | Pneumocystosis |
| 176.9 | http://hl7.org/fhir/sid/icd-9-cm | Kaposi's sarcoma, unspecified site |
| 42 | http://hl7.org/fhir/sid/icd-9-cm | Operations on esophagus |
| 10901-7 | http://loinc.org | HIV 2 gp125 Ab [Presence] in Serum by Immunoblot |
| 10902-5 | http://loinc.org | HIV 2 gp36 Ab [Presence] in Serum by Immunoblot |
| 11078-3 | http://loinc.org | HIV 2 gp80 Ab [Presence] in Serum by Immunoblot |
| 11079-1 | http://loinc.org | HIV 2 p26 Ab [Presence] in Serum by Immunoblot |
| 11080-9 | http://loinc.org | HIV 2 p53 Ab [Presence] in Serum by Immunoblot |
| 11081-7 | http://loinc.org | HIV 2 p56 Ab [Presence] in Serum by Immunoblot |
| 11082-5 | http://loinc.org | HIV 2 p68 Ab [Presence] in Serum by Immunoblot |
| 13920-4 | http://loinc.org | HIV 2 p41 Ab [Presence] in Serum by Immunoblot |
| 21334-8 | http://loinc.org | HIV 2 gp105 Ab [Presence] in Serum by Immunoblot |
| 21335-5 | http://loinc.org | HIV 2 gp120 Ab [Presence] in Serum by Immunoblot |
| 21336-3 | http://loinc.org | HIV 2 gp15 Ab [Presence] in Serum by Immunoblot |
| 21337-1 | http://loinc.org | HIV 2 gp34 Ab [Presence] in Serum by Immunoblot |
| 21338-9 | http://loinc.org | HIV 2 p31 Ab [Presence] in Serum by Immunoblot |
| 21339-7 | http://loinc.org | HIV 2 p55 Ab [Presence] in Serum by Immunoblot |
| 21340-5 | http://loinc.org | HIV 2 p58 Ab [Presence] in Serum by Immunoblot |
| 22358-6 | http://loinc.org | HIV 2 Ab [Units/volume] in Serum |
| 25841-8 | http://loinc.org | HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection |
| 25842-6 | http://loinc.org | HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection |
| 30361-0 | http://loinc.org | HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay |
| 31073-0 | http://loinc.org | HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot |
| 33806-1 | http://loinc.org | HIV 2 IgG Ab [Presence] in Serum by Immunoblot |
| 33807-9 | http://loinc.org | HIV 2 IgG Ab [Presence] in Serum |
| 34699-9 | http://loinc.org | HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection |
| 42768-2 | http://loinc.org | HIV 1 and 2 Ab [Interpretation] in Serum Narrative |
| 43185-8 | http://loinc.org | HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot |
| 45212-8 | http://loinc.org | HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot |
| 47029-4 | http://loinc.org | HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot |
| 51786-2 | http://loinc.org | HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay |
| 5224-1 | http://loinc.org | HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay |
| 5225-8 | http://loinc.org | HIV 2 Ab [Presence] in Serum by Immunoblot |
| 56888-1 | http://loinc.org | HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay |
| 57976-3 | http://loinc.org | HIV 2 gp140 Ab [Presence] in Serum by Immunoblot |
| 57977-1 | http://loinc.org | HIV 2 p16 Ab [Presence] in Serum by Immunoblot |
| 57978-9 | http://loinc.org | HIV 2 p34 Ab [Presence] in Serum by Immunoblot |
| 58900-2 | http://loinc.org | HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay |
| 62456-9 | http://loinc.org | HIV 2 p15 Ab [Presence] in Serum by Immunoblot |
| 6429-5 | http://loinc.org | HIV identified in Blood by Organism specific culture |
| 6430-3 | http://loinc.org | HIV identified in Semen by Organism specific culture |
| 6431-1 | http://loinc.org | HIV identified in Specimen by Organism specific culture |
| 69353-1 | http://loinc.org | HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection |
| 69354-9 | http://loinc.org | HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
| 69668-2 | http://loinc.org | HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay |
| 7919-4 | http://loinc.org | HIV 2 Ab [Presence] in Serum |
| 9836-8 | http://loinc.org | HIV proviral DNA [Presence] in Blood by Probe with amplification |
| LP14307-0 | http://loinc.org | HIV 1 |
| LP16715-2 | http://loinc.org | HIV 1+2 |
| LP16716-0 | http://loinc.org | HIV 2 |
| LP29063-2 | http://loinc.org | HIV reverse transcriptase gene |
| LP30901-0 | http://loinc.org | HIV protease gene |
| LP32723-6 | http://loinc.org | HIV reverse transcriptase+protease gene |
| LP36650-7 | http://loinc.org | HIV 1 & 2 |
| LP36876-8 | http://loinc.org | HIV nucleoside reverse transcriptase gene |
| LP36877-6 | http://loinc.org | HIV nonnucleoside reverse transcriptase gene |
| LP38420-3 | http://loinc.org | HIV identified |
| LP38459-1 | http://loinc.org | HIV 1+2 Ab |
| LP38463-3 | http://loinc.org | HIV 2 Ab |
| LP62411-1 | http://loinc.org | HIV 1+O+2 Ab |
| 152535 | http://www.nlm.nih.gov/research/umls/rxnorm | Zovirax |
| 281 | http://www.nlm.nih.gov/research/umls/rxnorm | acyclovir |
| 111880001 | http://snomed.info/sct | Acute human immunodeficiency virus infection (disorder) |
| 420721002 | http://snomed.info/sct | Acquired immunodeficiency syndrome-associated disorder (disorder) |
| 0575F | http://www.ama-assn.org/go/cpt | HIV RNA control plan of care, documented (HIV) |
| 3292F | http://www.ama-assn.org/go/cpt | HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr) |
| 3490F | http://www.ama-assn.org/go/cpt | History of AIDS-defining condition (HIV) |
| 3491F | http://www.ama-assn.org/go/cpt | HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV) |
| 3492F | http://www.ama-assn.org/go/cpt | History of nadir CD4+ cell count <350 cells/mm3 (HIV) |
| 3493F | http://www.ama-assn.org/go/cpt | No history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV) |
| 3494F | http://www.ama-assn.org/go/cpt | CD4+ cell count <200 cells/mm3 (HIV) |
| 3495F | http://www.ama-assn.org/go/cpt | CD4+ cell count 200 - 499 cells/mm3 (HIV) |
| 3496F | http://www.ama-assn.org/go/cpt | CD4+ cell count >/=500 cells/mm3 (HIV) |
| 3497F | http://www.ama-assn.org/go/cpt | CD4+ cell percentage <15% (HIV) |
| 3498F | http://www.ama-assn.org/go/cpt | CD4+ cell percentage >/=15% (HIV) |
| 3500F | http://www.ama-assn.org/go/cpt | CD4+ cell count or CD4+ cell percentage documented as performed (HIV) |
| 3502F | http://www.ama-assn.org/go/cpt | HIV RNA viral load below limits of quantification (HIV) |
| 3503F | http://www.ama-assn.org/go/cpt | HIV RNA viral load not below limits of quantification (HIV) |
| 3510F | http://www.ama-assn.org/go/cpt | Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD) |
| 3511F | http://www.ama-assn.org/go/cpt | Chlamydia and gonorrhea screenings documented as performed (HIV) |
| 3512F | http://www.ama-assn.org/go/cpt | Syphilis screening documented as performed (HIV) |
| 3513F | http://www.ama-assn.org/go/cpt | Hepatitis B screening documented as performed (HIV) |
| 3514F | http://www.ama-assn.org/go/cpt | Hepatitis C screening documented as performed (HIV) |
| 3515F | http://www.ama-assn.org/go/cpt | Patient has documented immunity to Hepatitis C (HIV) |
| 4149F | http://www.ama-assn.org/go/cpt | Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD) |
| 4270F | http://www.ama-assn.org/go/cpt | Patient receiving potent antiretroviral therapy for 6 months or longer (HIV) |
| 4271F | http://www.ama-assn.org/go/cpt | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV) |
| 4274F | http://www.ama-assn.org/go/cpt | Influenza immunization administered or previously received (HIV) (P-ESRD) |
| 4276F | http://www.ama-assn.org/go/cpt | Potent antiretroviral therapy prescribed (HIV) |
| 4279F | http://www.ama-assn.org/go/cpt | Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV) |
| 4280F | http://www.ama-assn.org/go/cpt | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV) |
| 4290F | http://www.ama-assn.org/go/cpt | Patient screened for injection drug use (HIV) |
| 4293F | http://www.ama-assn.org/go/cpt | Patient screened for high-risk sexual behavior (HIV) |
| 86689 | http://www.ama-assn.org/go/cpt | Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot) |
| 86701 | http://www.ama-assn.org/go/cpt | Antibody; HIV-1 |
| 86702 | http://www.ama-assn.org/go/cpt | Antibody; HIV-2 |
| 86703 | http://www.ama-assn.org/go/cpt | Antibody; HIV-1 and HIV-2, single result |
| 87389 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result |
| 87390 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 |
| 87391 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2 |
| 87534 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique |
| 87535 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed |
| 87536 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed |
| 87537 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique |
| 87538 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed |
| 87539 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed |
| 87900 | http://www.ama-assn.org/go/cpt | Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics |
| 87901 | http://www.ama-assn.org/go/cpt | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions |
| 87903 | http://www.ama-assn.org/go/cpt | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested |
| 87904 | http://www.ama-assn.org/go/cpt | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure) |
| 87906 | http://www.ama-assn.org/go/cpt | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion) |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |
History
| Date | Action | Author | Verifier | Comment |
| 2023-01-31 | revise | John Moehrke | Administrative touchup to add history | |
| 2022-07-27 | create | John Moehrke | John F. Moehrke | Initial ValueSet as per the C2S layout |